Results 21 to 30 of about 16,883 (239)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Viruses, 2023
Background: Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients. Methods: Retrospective multicenter study including AIDS- or late-presenting (def.
Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto   +15 more
doaj   +1 more source

Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study

Molecules, 2022
There is increasing awareness of an association between the uptake of the HIV integrase inhibitor, dolutegravir, in first-line antiretroviral regimens with unusual weight gain and development of the metabolic syndrome, particularly in African women ...
Annette J. Theron, Ronald Anderson, Morris Madzime, Theresa M. Rossouw, Helen C. Steel, Pieter W. A. Meyer, Moloko C. Cholo, Luyanda L. I. Kwofie, Charles Feldman, Gregory R. Tintinger   +9 more
doaj   +1 more source

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC Infectious Diseases, 2019
Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto   +12 more
doaj   +1 more source

Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal

Southern African Journal of HIV Medicine, 2023
We report a case of dolutegravir resistance in KwaZulu-Natal in a 13-year-old male two years after starting dolutegravir. Resistance most likely developed due to poor adherence as a result of psychosocial issues.
Sibongiseni Malinga, Aabida Khan, Moherndran Archary   +2 more
doaj   +1 more source

Improvements in cognitive performance switching from efavirenz‐ to dolutegravir‐based antiretroviral therapy in South African people with HIV: the CONNECT study [PDF]

Alzheimers Dement
Abstract Background HIV can cause cognitive impairment, although it is unclear how commonly. This may partly be driven by HIV ribonucleic acid (RNA) cerebrospinal fluid (CSF) escape (ie. HIV RNA in CSF>plasma). Recently the World Health Organisation recommended first‐line HIV treatment change from efavirenz‐ to dolutegravir‐based antiretroviral therapy
Nightingale S.
europepmc   +2 more sources

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens

South African Journal of Psychiatry, 2023
Background: Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART).
Janine Rodrigues, Karishma Lowton
doaj   +1 more source

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review

Viruses, 2023
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on
Kaiming Tao, Soo-Yon Rhee, Carolyn Chu, A. Avalos, A. K. Ahluwalia, Ravindra K. Gupta, Michael I. Jordan, R. Shafer   +7 more
semanticscholar   +1 more source

Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland

SAGE Open Medicine, 2016
Objective: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. Methods: Retrospective health care
Sarmad Waqas, Mairead O’Connor, Ciara Levey, Paddy Mallon, Gerard Sheehan, Anjali Patel, Gordana Avramovic, John S Lambert   +7 more
doaj   +1 more source

Dolutegravir potentiates platelet activation by a calcium-dependent, ionophore-like mechanism

Journal of Immunotoxicology, 2022
Dolutegravir is a highly potent HIV integrase strand transfer inhibitor that is recommended for first-line anti-retroviral treatment in all major treatment guidelines.
Morris Madzime, Annette J. Theron, Ronald Anderson, Gregory R. Tintinger, Helen C. Steel, Pieter W. A. Meyer, Jan G. Nel, Charles Feldman, Theresa M. Rossouw   +8 more
doaj   +1 more source

Intranasal Administration of Dolutegravir-Loaded Nanoemulsion-Based In Situ Gel for Enhanced Bioavailability and Direct Brain Targeting

Gels, 2023
Dolutegravir’s therapeutic effectiveness in the management of neuroAIDS is mainly limited by its failure to cross the blood–brain barrier. However, lipid-based nanovesicles such as nanoemulsions have demonstrated their potential for the brain targeting ...
Anroop B Nair, S. Chaudhary, S. Jacob, Dhruvan Patel, P. Shinu, Hiral Shah, Ankit Chaudhary, Bandar E. Aldhubiab, Rashed M. Almuqbil, Ahmed S. Alnaim, Fatemah Alqattan, Jigar N. Shah   +11 more
semanticscholar   +1 more source